What is the role of 15-deoxyspergualin in the treatment of granulomatosis with polyangiitis (GPA)?

Updated: Aug 31, 2021
  • Author: Christopher L Tracy, MD; Chief Editor: Herbert S Diamond, MD  more...
  • Print

The drug 15-deoxyspergualin (0.5 mg/kg/day subcutaneous or intravenous) is a synthetic derivative of spergualin, a protein from Bacillus laterosporus that is capable of preventing T-cell and B-cell maturation. The medication is licensed in Japan for recurrent kidney transplant rejection. In addition, 15-desoxyspergualin has been used with some success in refractory GPA cases and in patients with contraindications to cytotoxic therapy. [103, 104, 105] It may offer a safer alternative to cyclophosphamide for induction therapy but is not yet supported for routine clinical use. [101]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!